Experimental cell treatment offers hope for tough kidney cancers
NCT ID NCT04696731
Summary
This early-stage trial is testing a new cell therapy called ALLO-316 for people with advanced kidney cancer that has spread. Researchers want to find the safest and most effective dose by giving patients different amounts of the treatment after they receive chemotherapy. The study includes adults whose cancer has continued to grow despite trying standard immunotherapy and targeted drug treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.